Source: VETSTEM Press Service
Analytical company RNC Pharma and portal Zooinform.ru published a comprehensive review of the Russian retail veterinary pharmaceutical market for 2025. According to the published data, the total market volume reached RUB 49.1 billion, which is 17.6% higher than in 2024. Physical sales volume reached 27 million minimum dosage units.
The key trend of the year was further strengthening of domestic manufacturers’ positions. Their share increased to 56% in value terms and 74% in volume terms. Veterinary drug production in Russia increased by 78% over four years — from 28 to 50 million packages.
Government support plays a significant role in this process: under the federal project “Veterinary Drugs,” RUB 5 billion has been allocated for development of new medicinal products and vaccines.
The reduction in imported product assortment — from more than 750 items in 2022 to fewer than 300 in 2025 — increased the need for high-quality domestic alternatives. In veterinary anesthesia, this niche is successfully occupied by VEZOTIL® — a tiletamine- and zolazepam-based product developed by VETSTEM LLC, a Skolkovo resident.
The product does not require a special license for purchase and storage by veterinary clinics, which is an important competitive advantage. According to clinical study results, VEZOTIL® demonstrated efficacy comparable to, and in some parameters exceeding, that of the foreign analog: 98% successful first-attempt inductions and an average anesthesia quality score of 9.2 out of 10.
VETSTEM LLC has a broad distribution network, ensuring product availability for veterinary clinics across the country. Market growth and government support for import substitution create favorable conditions for further development of VEZOTIL® as a leading domestic anesthetic in veterinary practice.